Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 30 clinical trials
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

This is a first-in-human, multi-center clinical study to determine the safety, Maximum Tolerated Dose (MTD) and/or Optimal Biological Dose (OBD) as well as the optimal schedule for intravenous (IV) and/or subcutaneous (SC) administrations of RO7293583 with or without obinutuzumab pretreatment, in participants with unresectable metastatic TYRP1-positive melanomas who have progressed …

malignant melanoma of skin
mucosal melanoma
measurable disease
BRAF
  • 0 views
  • 17 Mar, 2022
  • 4 locations
MGD019 DART® Protein in Unresectable/Metastatic Cancer

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of lorigerlimab. This Phase 1, open-label study will characterize safety, dose-limiting toxicities (DLTs), and maximum tolerated/administered dose (MTD/MAD) of MGD019. Dose escalation will occur in a 3+3+3 design in patients with …

malignant melanoma of skin
solid tumour
targeted therapy
solid neoplasm
ROS1
  • 18 views
  • 13 May, 2022
  • 29 locations
A Study of SGN-CD228A in Advanced Solid Tumors

This trial will study SGN-CD228A to find out whether it is an effective treatment for different kinds of cancer. It will also look at what side effects (unwanted effects) may occur. The study will have two parts. Part 1 of the study will find out how much SGN-CD228A should be …

malignant melanoma of skin
lung carcinoma
solid tumour
adenocarcinoma
her2/neu-negative breast cancer
  • 16 views
  • 13 May, 2022
  • 14 locations
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)

RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.

malignant melanoma of skin
solid tumour
solid neoplasm
nivolumab
squamous cell carcinoma
  • 127 views
  • 14 May, 2022
  • 44 locations
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

This trial will look at a drug called SEA-TGT (also known as SGN-TGT) to find out whether it is safe for patients with solid tumors and lymphomas. It will study SEA-TGT to find out what its side effects are. A side effect is anything the drug does besides treating cancer. …

solid tumour
prednisone
vincristine
pd-1 inhibitor
large b-cell lymphoma
  • 102 views
  • 15 May, 2022
  • 29 locations
MoleGazer Development Feasibility Study

Melanoma (skin cancer) frequently develops from existing moles on the skin. Current practice relies on expert dermatologists being able to successfully identify new/changing moles in individuals with multiple moles. Total body photography (TBP-high-quality images of the entire skin) can track and monitor moles over time to detect melanoma. However, TBP …

skin cancer screening
cancer
  • 0 views
  • 30 Sep, 2021
  • 1 location
Irradiation of Melanoma in a Pulse

This is a single center phase I, first-in-human, dose escalation study of FLASH therapy in patients with metastases of melanoma. The trial is based on escalating single doses of FLASH therapy administered to skin melanoma metastases using the Mobetron with high dose rate (HDR) functionality. The aim of the study …

  • 0 views
  • 05 Sep, 2021
  • 1 location
Neoadjuvant Atezolizumab in Cutaneous Melanoma

The purpose of this research study is to see whether using atezolizumab before surgery is safe and does not cause side effects that delay surgery in participants with cutaneous melanoma that has not spread to other areas of the body (non-metastatic) and can be removed by surgery (resectable) but has …

malignant melanoma of skin
cancer
  • 0 views
  • 21 Mar, 2022
  • 1 location
Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome

To assess whether vitamin D supplementation after surgery of a first cutaneous malignant melanoma protects against relapse of the disease.

  • 12 views
  • 26 Jan, 2021
  • 4 locations
Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6 (ARTISTRY-6)

This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma following prior anti-PD-[L]-1 therapy

malignant melanoma of skin
targeted therapy
mucosal melanoma
metastatic melanoma
cytotoxic t-lymphocyte antigen 4
  • 0 views
  • 26 Mar, 2022
  • 9 locations